B. Riley raised the firm’s price target on Journey Medical (DERM) to $12 from $11 and keeps a Buy rating on the shares. Journey Medical delivered strong Q4 execution, with Emrosi generating $14.7M in FY25 revenues over nine months and prescription volumes growing about 50% sequentially, supporting a robust exit into 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: